July 17, 2024
Exceptional research recognized at annual meeting for advancing the science of immunology
The Federation of Clinical Immunology Societies (FOCIS) honors outstanding scientists each year through awards that recognize exceptional research. Offering a forum where leading researchers can come together to pursue breakthroughs in disease therapy, FOCIS members share knowledge and identify treatment commonalities to help those affected by immunological disorders.
Benaroya Research Institute (BRI) proudly congratulates five of its scientists for being named 2024 FOCIS award recipients.
Recipients of a FOCIS Research Award:
- Hai Nguyen, PhD (staff scientist, James Lab): “Single-Cell Analysis of CD8 T Cells Reveals Autoantigen-Specific Signatures of Teplizumab Treatment in At-Risk Subjects From the TrialNet 10 Study”
- John Ray, PhD (assistant member, Center for Systems Immunology; principal investigator, Ray Lab): “Genome-Wide Autoimmune Genetic Variant Perturbations Connect Genetic Risk To Primary T Cell Expression and Function”
- Ritika Tewari, PhD (staff scientist, Buckner Lab): “Expanding Our Understanding of PDC-E2 T Cell Responses in PBC and Their Application for Eng Treg Therapy”
- Soo Jung Yang, PhD (research assistant member, Center for Translational Immunology; principal investigator, Yang Lab): “TCR Avidity Influences Signaling and Function of Engineered Treg”
Recipient of a FOCIS Center of Excellence (FCE) Award:
- Aisha Callebaut, PhD (postdoctoral research associate, James Lab): “Non-Enzymatic Asn Deamidation of GAD65 Generates HLA-DRB1*03:01-Restricted Neoepitopes in Type 1 Diabetes”
Recipients of a FOCIS Poster of Merit recognition:
- Hai Nguyen, PhD (staff scientist, James Lab): “Single-Cell Analysis of CD8 T Cells Reveals Autoantigen-Specific Signatures of Teplizumab Treatment in At-Risk Subjects From the TrialNet 10 Study”
- John Ray, PhD (assistant member, Center for Systems Immunology; principal investigator, Ray Lab): “Genome-Wide Autoimmune Genetic Variant Perturbations Connect Genetic Risk To Primary T Cell Expression and Function”